Market Currents
BMO Capital weighs in on the FDA rejection of Amgen's (AMGN -1.3%) Xgeva cancer drug, saying...
-
Wednesday, February 8, 2012, 1:17 PM ETBMO Capital weighs in on the FDA rejection of Amgen's (AMGN -1.3%) Xgeva cancer drug, saying that if the firm fails to ultimately win approval for use of the drug it could lose revenue of as much as $1B.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
